Dong Fang Liu
Chief Tech/Sci/R&D Officer at NUVATION BIO INC.
Net worth: 21 840 $ as of 2024-03-30
Profile
Dong Fang Liu is currently the Chief Medical Officer at Nuvation Bio, Inc. Prior to this, he held positions as the Group Director-Oncology Clinical Research at Bristol Myers Squibb Co. and as the Executive Director at Celgene Corp.
From 2019 to 2021, he served as the Chief Medical Officer at 3D Medicines, Inc. Dr. Liu obtained a doctorate degree from the Massachusetts Institute of Technology in 2001.
He also holds a graduate degree from the University of Toledo (Ohio) conferred in 1997 and an undergraduate degree from Beijing Medical University received in 1993.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-28 | 6,000 ( 0.00% ) | 21 840 $ | 2024-03-30 |
Dong Fang Liu active positions
| Companies | Position | Start |
|---|---|---|
| NUVATION BIO INC. | Chief Tech/Sci/R&D Officer | 2022-07-17 |
Former positions of Dong Fang Liu
| Companies | Position | End |
|---|---|---|
| 3D MEDICINES INC. | Chief Tech/Sci/R&D Officer | 2021-02-28 |
| CELGENE | Director/Board Member | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Training of Dong Fang Liu
| Massachusetts Institute of Technology | Doctorate Degree |
| University of Toledo (Ohio) | Graduate Degree |
| Beijing Medical University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| NUVATION BIO INC. | Health Technology |
| 3D MEDICINES INC. | Health Technology |
| Private companies | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Stock Market
- Insiders
- Dong Fang Liu